Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

France flag France · Delayed Price · Currency is EUR
0.437
+0.007 (1.63%)
Last updated: Apr 28, 2026, 1:51 PM CET
15.00%
Market Cap 8.05M
Revenue (ttm) 1.74M
Net Income (ttm) 6.27M
Shares Out 18.12M
EPS (ttm) 0.35
PE Ratio 1.28
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 15,232
Open 0.441
Previous Close 0.430
Day's Range 0.433 - 0.448
52-Week Range 0.280 - 0.920
Beta -0.29
RSI 40.51
Earnings Date May 4, 2026

About EPA:ALOPM

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 14
Stock Exchange Euronext Paris
Ticker Symbol ALOPM
Full Company Profile

Financial Performance

In 2024, EPA:ALOPM's revenue was 1.64 million, a decrease of -6.02% compared to the previous year's 1.74 million. Losses were -7.21 million, -10.89% less than in 2023.

Financial Statements

News

There is no news available yet.